Robert Mabry

Robert Mabry

Company: Orna Therapeutics

Job title: Chief Scientific Officer


Determining the Progression of In Vivo in Indications Beyond Oncology Such As Autoimmune Diseases 2:15 pm

Reflecting on the application of ex vivo cell and gene therapies to consider the in vivo potential of this indication Analyzing pre-clinical data suggesting promise for indications outside of oncology to begin mapping out future progression towards the clinics Examining how the chronic but not life-threatening nature of autoimmune diseases may impact the safety concerns…Read more

day: Conference Day Two

Industry Leader’s Fireside Chat: Supercharging In Vivo as the Frontier of Cell Therapy & Comparing to Ex Vivo 9:00 am

Accentuating the bottlenecks of ex vivo therapies, such as the need for costly manufacturing processes and limited access, to consider the need to move towards a new engineering technique Championing in vivo therapies by highlighting the solutions they could bring to the ex vivo cell therapy and gene editing field Reaffirming the shift of interest…Read more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2024 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.